Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + nab-paclitaxel with or without ciprofloxacin in second-line metastatic pancreatic adenocarcinoma
MOH_2022-11-21_012145Phase 2Not yet recruiting
- Sponsor
- דוקטור תמר בלר
- Start
- Nov 2022
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ciprofloxacin, gemcitabine and paclitaxel in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by דוקטור תמר בלר. Primary endpoint: Progression-free survival. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
ciprofloxacingemcitabinepaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on MOH_2022-11-21_012145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-11-21_012145.